tyrphostin ag 1024 has been researched along with erlotinib hydrochloride in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
1 other study(ies) available for tyrphostin ag 1024 and erlotinib hydrochloride
Article | Year |
---|---|
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cetuximab; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Quinazolines; Tyrphostins | 2005 |